louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03957044: the Effect of Vestibular Rehabilitation in Autistic Children
Official title: The Effect of Vestibular Rehabilitation on Sensory Profile and Postrotary Nystagmus in Autistic Children
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Autistic Spectrum Disorder
Vestibular Disorder
Sensory Integration Disorder
Lead sponsor: Istinye University
Sponsor class: OTHER
First posted: 2019-05-21
Enrollment: 22
Sex: ALL
Minimum age (years): 3
Maximum age (years): 10
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study was conducted to clarify the effect of vestibular education for autistic children on "sensory profile" and "postrotary nystagmus". In the study, the results of the two groups were compared through the treatment of sensory integration: the once who got the education and the once who did not. For this study, 26 autistic children were included who joined the " Çatalca District Unit of Disabled the Project of No Disabilities ", who was diagnosed with autism, who was 3-10 years (older than 36 months younger than 11 years). For each child, the analysis of the sensory integration and nystagmus was applied twice; at the beginning and at the end of the research. At the beginning of the research, the children were divided into two groups randomly drawn by lots. The first group was given the education of sensory integration with vestibular education and the second group was given the education of sensory integration without vestibular education. Both groups were educated for 10 weeks, 2 days a week with 40- minute sessions.


Eligibility criteria: Inclusion Criteria:

* The study included autistic children aged between 3 and 10 years (36 months, 11 years old) who were diagnosed with autism according to the Diagnostic and Statistical Manual of Mental Disorders criteria. The families of all children who participated in the study were informed and their written permissions were obtained.

Exclusion Criteria:

* Children who were not diagnosed with autism and who had previously received treatment for sensory integrity were excluded. The children who participated in the study had independent walking problems, those with lack of extremity, those with hip dislocation, those with postural anomalies, those who had an operation, those with infectious diseases, those with additional diagnoses with autism (such as cerebral palsy), patients with seizures, traumatic postpartum trauma, and motor development disorder. those with the postural disorder were not included in the study

Primary outcomes:
measure: sensory profile test
timeFrame: 10 weeks
measure: postrotary nystagmus test
timeFrame: 10 weeks
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04822844: Implementing a Nurse-Driven Aromatherapy Protocol to Decrease the Effect of Postoperative Nausea and Vomiting
Official title: Implementing a Nurse-Driven Aromatherapy Protocol to Decrease the Effect of Postoperative Nausea and Vomiting
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Postoperative Nausea and Vomiting (PONV)
Keywords: aromatherapy
Lead sponsor: The University of Texas Health Science Center, Houston
Sponsor class: OTHER
Collaborators: name: HCA Houston Healthcare Southeast Hospital
First posted: 2021-03-30
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: This is a quality improvement project that aims to assess the effect of nurse-driven administration of essential oil aromatherapy on postoperative nausea and vomiting (PONV) in patients while in the post-anesthesia care unit (PACU) after general anesthesia.

Detailed description: In this three-month quality improvement project, nurse-driven aromatherapy will be offered to all patients in the main PACU setting at the Hospital Corporation of America (HCA) Houston Healthcare Southeast Hospital after they have undergone surgical procedures with general anesthesia, with the exception of patients who report allergies or sensitivity to ginger or lavender essential oils (EO) and patients who wish to be excluded from the project.

Eligibility criteria: Inclusion Criteria:

* PACU patients who are in the main PACU setting at HCA Houston Healthcare Southeast Hospital after having undergone general anesthesia for a surgical procedure

Exclusion Criteria:

* patients with allergies or sensitivity to ginger or lavender essential oils
* patients who wish to be excluded from the project

Primary outcomes:
measure: Number of Post-Operative Nausea and Vomiting Episodes While in the PACU
timeFrame: during stay in PACU (about 45-60 minutes)
Secondary outcomes:
measure: PACU Length of Stay
timeFrame: time between PACU admission and PACU discharge (about 45-60 minutes)
measure: Number of Participants Who Use Antiemetics While in the PACU
timeFrame: during stay in PACU (about 45-60 minutes)
measure: Patient Satisfaction as Assessed by the Press Ganey Patient Satisfaction Survey
timeFrame: at discharge (about 1 hour after PACU admission)
Other outcomes:
Locations:
city: Pasadena
country: United States
facility: HCA Houston Healthcare Southeast Hospital
state: Texas
Study officials:
affiliation: The University of Texas Health Science Center, Houston
name: Julie George, RN, MSN
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01503944: A Trial of 18F-AV-133 and 18F-AV-45 Positron Emission Tomography (PET)
Official title: Detection of Striatal Dopaminergic Degeneration and Neocortical Amyloid Pathology in Patients With Dementia With Lewy Bodies, Alzheimer's Disease, Parkinson's Disease, and Healthy Elderly Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Dementia With Lewy Bodies
Alzheimer's Disease
Parkinson's Disease
Lead sponsor: Avid Radiopharmaceuticals
Sponsor class: INDUSTRY
First posted: 2012-01-04
Enrollment: 30
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: The purpose of this study is to evaluate the ability to identify individuals with dopaminergic degeneration in group of patients with a clinical diagnosis of either dementia with Lewy bodies (DLB) or idiopathic Parkinson's disease and to differentiate them from Alzheimer's disease (AD) and control subjects.


Eligibility criteria: Inclusion Criteria DLB:

* Male or female \> 50 years of age
* Meet the diagnostic criteria for probable DLB as established by the DLB Consortium (McKeith et al., 2005)

Inclusion Criteria AD:

* Male or female \> 50 years of age
* Meet the NINCDS criteria for probable AD and have a Mini Mental State Examination (MMSE) score at screening between 10 and 24 inclusive

Inclusion Criteria PD:

* Male or female \> 50 years of age
* Have probable PD according to the following criteria (Gelb et al., 1999):

  * Presence of 2 of the following 3 features: rest tremor, rigidity, bradykinesia;
  * Documented history of a sustained (\>6 months) improvement to Levodopa (L-DOPA) or a dopamine agonist
  * Absence of atypical clinical features or other possible signs or symptoms suggesting another cause of parkinsonism such as a history of frequent falls as a prominent early feature, localized brain lesion(s) or neuroleptic use
  * Asymmetric onset
* A diagnosis of PD made within the 4 years prior to enrollment

Normal subjects:

* Are males or females \> 50 years of age
* Have a MMSE score \> 29, and are cognitively normal on the psychometric test battery at screening
* Have no signs or symptoms of clinically meaningful parkinsonism

Exclusion Criteria:

* Have a history or current diagnosis of other neurologic disease
* Have evidence of clinically significant cerebrovascular disease
* Have evidence from MRI or other biomarker studies that suggests the presence of a CNS pathology other than that associated with the study diseases

Primary outcomes:
measure: 18F-AV-133 striatal to occipital standard uptake value ratio
timeFrame: Four Weeks
Secondary outcomes:
measure: 18F-AV-45 cortical to cerebellar standard uptake value ratio
timeFrame: Four Weeks
Other outcomes:
Locations:
city: Sun City
country: United States
facility: Research Site
state: Arizona
city: Philadelphia
country: United States
facility: Research Site
state: Pennsylvania
Study officials:
affiliation: Avid Radiopharmaceuticals
name: Chief Medical Officer
role: STUDY_DIRECTOR
References:
Clinical trial NCT06837844: Combined Intrathecal Dexmedetomidine and Adductor Canal Block for Analgesia After Total Knee Arthroplasty
Official title: Combined Intrathecal Dexmedetomidine and Adductor Canal Block for Analgesia After Total Knee Arthroplasty: A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Intrathecal Dexmedetomidine
Adductor Canal Block
Analgesia
Total Knee Arthroplasty
Lead sponsor: Kafrelsheikh University
Sponsor class: OTHER
First posted: 2025-02-20
Enrollment: 75
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this work is to evaluate the effect of combined intrathecal dexmedetomidine and adductor canal block for analgesia after total knee arthroplasty (TKA).

Detailed description: Effective postoperative pain management is essential for improving patient outcomes following knee surgery, facilitating early mobilization, and reducing the risk of complications.

The adductor canal block (ACB) is a nerve block of Hunters canal, which includes the saphenous and vastus medialis nerves. Additionally, other sensory nerves, such as the femoral nerve, medial cutaneous nerve, and both the anterior branch and terminal end of the posterior branch of the obturator nerve to some extent as it enters the distal part of the canal are blocked by the ACB.

Dexmedetomidine (DXM) a highly selective α2 adrenergic agonist with sedative, anxiolytic, analgesic, sympatholytic and antihypertensive effects.

Eligibility criteria: Inclusion Criteria:

* Age from 18 to 75 years.
* Both sexes.
* American Society of Anesthesiology (ASA) physical status I-II.
* Scheduled for total knee arthroplasty under spinal anesthesia.

Exclusion Criteria:

* Patients with neurological or intellectual disability.
* History of allergy to local anesthetics or dexmedetomidine .
* Infection at the injection site.
* Prolonged use of analgesic or sedative medications.
* Coagulation abnormalities.
* Pregnancy.
* Obesity \[body mass index (BMI) \> 30 kg/m2\].

Primary outcomes:
measure: Total morphine consumption
timeFrame: 48 hours postoperatively
Secondary outcomes:
measure: Time to the 1st rescue analgesia
timeFrame: 48 hours postoperatively
measure: Degree of pain
timeFrame: 48 hours postoperatively
measure: Heart rate
timeFrame: In post-anesthesia care unit (PACU) (Up to 1 hour)
measure: Mean arterial pressure
timeFrame: In post-anesthesia care unit (PACU) (Up to 1 hour)
measure: Degree of patient satisfaction
timeFrame: 48 hours postoperatively
measure: Incidence of adverse events
timeFrame: 48 hours postoperatively
Other outcomes:
Locations:
city: Kafr Ash Shaykh
country: Egypt
facility: Kafrelsheikh University
state: Kafrelsheikh
Study officials:
References:
Clinical trial NCT06260644: Evaluation of Using Self-adhering Flowable Resin Composite in Repairing Old Defective Resin Composite Restorations Over 18 Months Follow up. (A Randomized Clinical Trial)
Official title: Evaluation of Using Self-adhering Flowable Resin Composite Versus Conventional Nano-filled Flowable Resin Composite in Repairing Old Defective Resin Composite Restorations Over 18 Months Follow up. (A Randomized Clinical Trial)
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Occlusal Caries
Keywords: flowable resin composite
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2024-02-15
Enrollment: 34
Sex: ALL
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: parallel assignment
Primary purpose: TREATMENT

Brief summary: This research proposal is evaluating the clinical performance of using self-adhering flowable resin composite in repairing old occlusal defective resin composite versus conventional flowable resin composite restoration over 18 months.


Eligibility criteria: Inclusion Criteria:

* Patients (18-35 y)
* patients with defective resin composite class I restorations that need repair.
* dental motivated patients who attends regularly.
* Vital posterior teeth with repairable defective resin composite class I restorations.
* Localized marginal defect or marginal staining FDI 3\& 4.
* Teeth with no or minimum mobility \& healthy peridontium.
* No history of any irreversible pulpal pain or necrosis in the teeth to be restored.

Exclusion Criteria:

* • Patients with defective restorations that dictate replacement

  * Uncooperative behavior limits the isolation techniques throughout the procedure.
  * Presence of parafunctional habits.
  * Patient with history of systemic medical disease, or any other serious relevant problem.
  * High caries risk patients. Periodontal disease that may affect the prognosis of the restoration or the tooth itself.
  * Fractured or visibly cracked teeth.
  * Symptoms of any pulp pathosis.
  * Defective resin composite restorations that dictate replacement.

Primary outcomes:
measure: Restoration clinical performance using FDI criteria
timeFrame: assessment will be done after the treatment then 6 months, 12 months and18 months.
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Faculty of Dentistry
Study officials:
References:
Clinical trial NCT02304744: Utrecht Coronary Biobank (UCORBIO)
Official title: Utrecht Coronary Biobank (UCORBIO)
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Coronary Artery Disease
Lead sponsor: UMC Utrecht
Sponsor class: OTHER
First posted: 2014-12-02
Enrollment: 3000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All adult (\>18 years) patients who undergo coronary angiography.

Brief summary: UCORBIO enrolls patients who undergo coronary angiography (for any indication). The investigators draw blood at the moment of insertion of the procedural arterial catheter.

At the moment of inclusion indication, procedural details, risk factor status, medication use and quality of life (RAND-36 and EuroQoL) is assessed. Patients are then followed-up for the occurrence of major adverse cardiovascular events for 5 years. During the follow-up period patients receive a questionnaire every year to check for hospital admissions. The questionnaires at two and five years of follow-up are enriched with quality of life questionnaires (RAND-36 and EuroQoL).


Eligibility criteria: Inclusion Criteria:

* Coronary angiography

Exclusion Criteria:

* Age \< 18 years.

Primary outcomes:
measure: major adverse cardiovascular events [MACE] (Stroke, myocardial infarction, coronary revascularization, death)
timeFrame: 5 years
Secondary outcomes:
Other outcomes:
Locations:
city: Utrecht
country: Netherlands
facility: UMC Utrecht
Study officials:
References:
citation: Gijsberts CM, Santema BT, Asselbergs FW, de Kleijn DP, Voskuil M, Agostoni P, Cramer MJ, Vaartjes I, Hoefer IE, Pasterkamp G, den Ruijter HM. Women Undergoing Coronary Angiography for Myocardial Infarction or Who Present With Multivessel Disease Have a Poorer Prognosis Than Men. Angiology. 2016 Jul;67(6):571-81. doi: 10.1177/0003319715604762. Epub 2015 Sep 7.
citation: Gijsberts CM, Agostoni P, Hoefer IE, Asselbergs FW, Pasterkamp G, Nathoe H, Appelman YE, de Kleijn DP, den Ruijter HM. Gender differences in health-related quality of life in patients undergoing coronary angiography. Open Heart. 2015 Aug 27;2(1):e000231. doi: 10.1136/openhrt-2014-000231. eCollection 2015.
citation: Gijsberts CM, Gohar A, Ellenbroek GH, Hoefer IE, de Kleijn DP, Asselbergs FW, Nathoe HM, Agostoni P, Rittersma SZ, Pasterkamp G, Appelman Y, den Ruijter HM. Severity of stable coronary artery disease and its biomarkers differ between men and women undergoing angiography. Atherosclerosis. 2015 Jul;241(1):234-40. doi: 10.1016/j.atherosclerosis.2015.02.002. Epub 2015 Feb 4.
Clinical trial NCT05346744: Occlusal Contact Trueness Affected by Six Chairside CAD/CAM Ceramic Materials
Official title: Quantitative Clinical Evaluation of the Occlusal Contact Trueness Affected by Six Chairside CAD/CAM Ceramic Materials：a Self-control Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Tooth Defect
Keywords: chairside CAD/CAM
ceramic materials
trueness
occlusal contact
Lead sponsor: Fujian Medical University
Sponsor class: OTHER
First posted: 2022-04-26
Enrollment: 10
Sex: ALL
Minimum age (years): 20
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: Ten individuals with tooth defect of mandibular first molar were selected to participate in the study. 6 crowns made from 6 chairside materials were milled by CEREC MCXL-EF mode for each mandibular first molar.
Primary purpose: TREATMENT

Brief summary: The aim of this clinic self-control study was to evaluate the trueness of occlusal contact affected by six ceramic materials during chairside fabricating process and offer recommendations for occlusal offset according to different ceramic materials in CEREC CAD/CAM design process.

Detailed description: Ten participants were selected for this study. InCoris TZl(ZIR), Celtra Duo(CD), IPS e.max(EMA), UPCERA LICI (LC), Vita enamic(ENA), UPCERA RUNCI (RC) were used to produce crowns for everyone by CEREC chairside CAD/CAM system. The milling trueness, postprocessing trueness and clinical adjustment of occlusal contact were quantitatively analyzed by the ATOS high-precision scanner and Geomagic reverse engineering software.

Eligibility criteria: Inclusion Criteria:

1. with one mandibular first molar requiring crown restoration that have undergone root canal treatment;
2. with complete permanent dentition;

Exclusion Criteria:

1. with carious lesions, abrasions, attrition, erosions or any kind of tooth defects;
2. with any kind of restorations in occlusal surfaces;
3. with any sign of temporomandibular dysfunction.

Primary outcomes:
measure: milling trueness(μm)
timeFrame: 1 week
measure: postprocessing trueness(μm)
timeFrame: 1 week
measure: clinical trueness(μm)
timeFrame: 1 week
Secondary outcomes:
Other outcomes:
Locations:
city: Fuzhou
country: China
facility: Fujian Medical University
state: Fujian
Study officials:
affiliation: Fujian Medical University
name: Hao Yu
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT07001644: Microneedling Versus Carboxytherapy in Stria Distensae Rubra
Official title: Microneedling Versus Carboxytherapy Either With or Without Platelet Rich Plasma in Treating Stria Distensae Rubra
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Striae Distensae
Keywords: striae distensae
striae rubra
microneedling
carboxytherapy
Lead sponsor: Alexandria University
Sponsor class: OTHER
First posted: 2025-06-03
Enrollment: 50
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is to evaluate and compare the efficacy and safety of microneedling and carboxytherapy either with or without platelet-rich plasma in the treatment of striae distensae rubra.


Eligibility criteria: Inclusion Criteria:

* Female patients.
* Age ranging from 18-45 years old.
* Fitzpatrick skin type III-IV.
* Striae distensae rubra on the abdomen (bilateral and more or less symmetrical).

Exclusion Criteria:

* Patients taking immunosuppressants or having any disease affecting wound healing including diabetes.
* Patients receiving systemic glucocorticoids for chronic health conditions.
* Patients with chronic dermatologic diseases such as psoriasis and vitiligo.
* Pregnant and lactating females.
* Patients with a tendency for keloid formation.
* Patients with endocrine disturbance.
* Patients with autoimmune diseases, systemic diseases such as severe anemia, respiratory, cardiac, renal or liver disorder.
* Patients with bleeding and coagulation disorders.
* Patients who received any form of treatment for their SD in the past 6 months.

Primary outcomes:
measure: Reduction in the size of the stria distensae rubra
timeFrame: group I: six sessions over 18 weeks , group II: 6 sessions over 12 weeks, followed in both groups by three months of follow up
Secondary outcomes:
Other outcomes:
Locations:
city: Alexandria
country: Egypt
facility: Alexandria Faculty of Medicine
Study officials:
affiliation: Alexandria University
name: professor doctor Amira Eid
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04470544: Camostat Mesilate Treating Patients With Hospitalized Patients With COVID-19
Official title: RECOVER: Phase 2 Randomized, Double-Blind Trial TREating Hospitalized Patients With COVID-19 With Camostat MesilatE, a TMPRSS2 Inhibitor
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Severe Acute Respiratory Syndrome
Lead sponsor: Academic and Community Cancer Research United
Sponsor class: OTHER
First posted: 2020-07-14
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To determine if the reduction in TMPRSS2 activity via direct inhibition with Camostat mesilate combined with standard of care (SOC) treatment will increase the proportion of patients alive and free from respiratory failure at Day 28 in SARS-CoV-2 as compared to SOC treatment with placebo.


Eligibility criteria: Inclusion Criteria:

* Laboratory confirmed SARS-CoV-2 infection
* Admitted to hospital for management of SARS-CoV-2
* Age ≥18
* Subject or legal representative able to give informed consent
* Ability to take all study drugs
* Respiratory status of 3 or greater on the WHO ordinal scale
* ALT or AST ≤5 x ULN
* Creatinine clearance ≥50 mL/min using the Cockroft-Gault formula
* Willingness to provide mandatory specimens for correlative research and banking

Exclusion Criteria:

* Women who are pregnant or breastfeeding
* Known hypersensitivity to the study drug, the metabolites or formulation excipient

Primary outcomes:
measure: Proportion of Patients Alive and Free From Respiratory Failure
timeFrame: 28 Days
Secondary outcomes:
measure: Proportion of Patients Alive and Free of Ventilator Use or ECMO
timeFrame: 28 Days
measure: Mortality Rate
timeFrame: 28 Days
measure: Clinical Change
timeFrame: 28 Days
measure: Adverse Event Grade 3 Plus Rate
timeFrame: 28 days
Other outcomes:
Locations:
city: Scottsdale
country: United States
facility: Mayo Clinic in Arizona
state: Arizona
city: Tucson
country: United States
facility: Tucson Medical Center
state: Arizona
Study officials:
affiliation: Academic and Community Cancer Research United
name: Alan H Bryce, M.D.
role: PRINCIPAL_INVESTIGATOR
References: